BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26748709)

  • 1. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
    Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
    Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
    Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
    Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
    Buisson R; Boisvert JL; Benes CH; Zou L
    Mol Cell; 2015 Sep; 59(6):1011-24. PubMed ID: 26365377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
    Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
    Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.
    Sarmento LM; Póvoa V; Nascimento R; Real G; Antunes I; Martins LR; Moita C; Alves PM; Abecasis M; Moita LF; Parkhouse RM; Meijerink JP; Barata JT
    Oncogene; 2015 Jun; 34(23):2978-90. PubMed ID: 25132270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
    Guo Y; Wang J; Benedict B; Yang C; van Gemert F; Ma X; Gao D; Wang H; Zhang S; Lieftink C; Beijersbergen RL; Te Riele H; Qiao X; Gao Q; Sun C; Qin W; Bernards R; Wang C
    Genome Med; 2021 Oct; 13(1):166. PubMed ID: 34663432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
    Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
    Mutat Res; 2023; 827():111834. PubMed ID: 37531716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
    Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
    Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe.
    Ashley AK; Shrivastav M; Nie J; Amerin C; Troksa K; Glanzer JG; Liu S; Opiyo SO; Dimitrova DD; Le P; Sishc B; Bailey SM; Oakley GG; Nickoloff JA
    DNA Repair (Amst); 2014 Sep; 21():131-9. PubMed ID: 24819595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation.
    Hammond EM; Dorie MJ; Giaccia AJ
    Cancer Res; 2004 Sep; 64(18):6556-62. PubMed ID: 15374968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
    Baranski Z; Booij TH; Cleton-Jansen AM; Price LS; van de Water B; Bovée JV; Hogendoorn PC; Danen EH
    J Pathol; 2015 Jul; 236(3):348-59. PubMed ID: 25757065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance.
    Wang M; Guo L; Wu Q; Zeng T; Lin Q; Qiao Y; Wang Q; Liu M; Zhang X; Ren L; Zhang S; Pei Y; Yin Z; Ding F; Wang HR
    Nat Commun; 2014 Sep; 5():4901. PubMed ID: 25249323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathways: Targeting ATR in Cancer Therapy.
    Karnitz LM; Zou L
    Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.